Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?

Hepatology

Volumn 54, Issue 6, 2011, Pages 1998-2004

  Poustchi, Hossein ^a,b   Farrell, Geoffrey C ^c   Strasser, Simone I ^d   Lee, Alice U ^e   Mccaughan, Geoffrey W ^d   George, Jacob ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF SYDNEY   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER SCREENING; COMMUNICATION SKILL; ECHOGRAPHY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER CANCER; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INFORMED CONSENT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATIENT PARTICIPATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052949031     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24581     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-823.
3. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009; 373: 614-616.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 1208-1236.
5. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. HEPATOLOGY 2000; 31: 330-335.
6. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91: 1479-1486.
7. Zhou XD, Tang ZY, Yu YQ, Ma ZC, Yang BH, Lu JZ, et al. Solitary minute hepatocellular carcinoma. A study of 14 patients. Cancer 1991; 67: 2855-2858.
8. Amarapurkar D. Screening for hepatocellular carcinoma: good enough but best yet to come. J Gastroenterol Hepatol; 25: 845-846.
9. Amarapurkar D, Han KH, Chan HL, Ueno Y. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J Gastroenterol Hepatol 2009; 24: 955-961.
10. Altman DG. Better reporting of randomised controlled trials: the CONSORT statement. BMJ 1996; 313: 570-571.
11. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
12. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204-209.
13. McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995; 13: 858-868.
14. Lilford RJ, Jackson J. Equipoise and the ethics of randomization. J R Soc Med 1995; 88: 552-559.
15. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999; 94: 2224-2229.
16. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989; 64: 2117-2120.
17. Heyward WL, Lanier AP, McMahon BJ, Fitzgerald MA, Kilkenny S, Paprocki TR. Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. JAMA 1985; 254: 3052-3054.
18. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer 1994; 69: 1157-1159.
19. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C. Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Soc Sci Med 1991; 32: 35-42.
20. Nievaard MA, de Vos R, de Haes JC, Levi M. [Reasons why patients do or do not participate in clinical trials; a systemic review of the literature.] Ned Tijdschr Geneeskd 2004; 148: 186-190.
21. Emanuel EJ, Emanuel LL. Four models of the physician-patient relationship. JAMA 1992; 267: 2221-2226.
22. Fleissig A, Jenkins V, Fallowfield L. Results of an intervention study to improve communication about randomised clinical trials of cancer therapy. Eur J Cancer 2001; 37: 322-331.
23. Gallet M, Aupetit JF, Servan E, Lestaevel M, Lopez M, Chassoux G. [Informed consent, what information is left after a therapeutic trial?] Arch Mal Coeur Vaiss 1994; 87: 39-45.
24. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 1987; 17: 20-24.
25. Ellis PM, Dowsett SM, Butow PN, Tattersall MH. Attitudes to randomized clinical trials amongst out-patients attending a medical oncology clinic. Health Expect 1999; 2: 33-43.
26. Slevin M, Mossman J, Bowling A, Leonard R, Steward W, Harper P, et al. Volunteers or victims: patients' views of randomised cancer clinical trials. Br J Cancer 1995; 71: 1270-1274.
27. Llewellyn-Thomas HA, McGreal MJ, Thiel EC. Cancer patients' decision making and trial-entry preferences: the effects of "framing" information about short-term toxicity and long-term survival. Med Decis Making 1995; 15: 4-12.
28. Domenighetti G, D'Avanzo B, Egger M, Berrino F, Perneger T, Mosconi P, et al. Women's perception of the benefits of mammography screening: population-based survey in four countries. Int J Epidemiol 2003; 32: 816-821.
29. Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA 2004; 291: 71-78.